Merz Group GmbH

About Merz Group

Merz Group is an international, family-owned healthcare company headquartered in Frankfurt am Main. The group comprises six business divisions: Merz Aesthetics (aesthetic medicine), Merz Therapeutics (neurology), Merz Lifecare (health and beauty products with brands such as tetesept, SOS and Zirkulin), Merz Real Estate, Merz Financial Investments and Merz Private Markets. At its Dessau production site (Merz Toxin Technology & Supply), Merz manufactures the active ingredient for botulinum toxin products as well as medical devices for global demand. The company sells its products in at least 25 countries; Merz Lifecare offers more than 650 products across over 11 brands. In the last fiscal year, the group achieved record revenue of €2.5 billion. By 2028, Merz is investing over €100 million in expanding the Dessau production site.

Site

Frankfurt am Main

Processes

Pharmaceutical development and production, Consumer healthcare / beauty products

Founded

1908

Industries

Pharmaceutical industry, Aesthetic medicine, Neurology, Consumer health / personal care

1. 01

   Pharmaceutical development

2. 02

   Active ingredient production (Dessau)

3. 03

   Manufacturing of medical devices and pharmaceuticals

4. 04

   Worldwide distribution

Locations

Product Areas

Company History

1. 1908/1918

   Founding: The website states the founding of Chemische Fabrik Merz & Co. by Friedrich Merz on 9 March 1918 in Frankfurt am Main; LinkedIn mentions a 118-year history dating back to 1908 – the sources contradict each other.

2. 2025

   Executive board expansion: Dr. Almuth Steinkühler becomes CFO (as of 01.11.2025); generational change in the shareholder family (January 2025).

3. 2026

   First issuance of a Schuldschein promissory note loan of €450 million; record revenue of €2.5 billion in the previous year.